Penghui Zhou

13PUBLICATIONS
65CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Major global burdens of diseaseInnate immunityBiologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 05, 2026
Membranolytic peptide programs immunogenic cell death for cancer therapy.

|Mar 03, 2026
GITR activation potentiates anti-tumor immunity of tumor-infiltrating lymphocytes expanded from glioblastoma by rescuing exhaustion.

Jiayi Zhou, Yinggui Yang, Ran Ye

|Jun 18, 2025
R9AP is a common receptor for EBV infection in epithelial cells and B cells.

Yan Li, Hua Zhang, Cong Sun

|Sep 30, 2024
Cancer cell-intrinsic biosynthesis of itaconate promotes tumor immunogenicity.

Zining Wang, Lei Cui, Yanxun Lin

|Dec 07, 2023
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation.

Fan Luo, Han Li, Wenjuan Ma

|Mar 09, 2023
Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.

Yuanzhong Wu, Liwen Zhou, Yezi Zou

Pageof 3

Frequent Collaborators

3 joint publications

Tiebang Kang

2 joint publications

Limin Zheng

2 joint publications

Yuanzhong Wu

2 joint publications

Shao-Cong Sun